Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

September 25, 2020September 25, 2020

Ninlaro Combo Fails to Halt Progression of Newly Diagnosed Multiple Myeloma, Trial Data Show

News

Adding Takeda’s Ninlaro (ixazomib) to Revlimid (lenalidomide) and dexamethasone failed to significantly extend life without disease progression in people newly diagnosed with multiple myeloma who are ineligible for autologous ... Read more

September 1, 2020September 1, 2020

Cilta-cel, CAR T-cell Treatment, Named Breakthrough Therapy in China

News

Legend Biotech and Janssen’s investigational CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) has been given breakthrough therapy designation in China as a potential treatment of relapsed or refractory multiple myeloma. ... Read more

August 24, 2020August 24, 2020

FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Kyprolis (carfilzomib) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma after one to three lines of therapy. Specifically, Darzalex ... Read more

August 10, 2020August 11, 2020

Ide-cel Application Resubmitted to FDA With Requested Data

News

Bristol Myers Squibb and Bluebird Bio have resubmitted a biologics license application (BLA) with additional information requested by the U.S. Food and Drug Administration to consider the approval of idecabtagene vicleucel (ide-cel) for adults with hard-to-treat multiple ... Read more

July 29, 2020July 29, 2020

First Patient Dosed in Trial Testing Belantamab Mafodotin, Nirogacestat Combo in RRMM Patients

News

A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s belantamab mafodotin, in combination with SpringWorks Therapeutics’ nirogacestat, in people with relapsed or refractory multiple myeloma, has dosed its first patient, SpringWorks ... Read more

July 27, 2020September 21, 2020

EU Approval Urged for GSX’s Belantamab Mafodotin for Heavily Treated Myeloma

News

GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approval in the European Union, by the Committee for Medicinal Products for Human Use (CHMP), for heavily treated multiple myeloma ... Read more

June 29, 2020June 29, 2020

Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows

News

First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with an autologous stem cell transplant (ASCT), according ... Read more

March 30, 2020April 14, 2020

Oncopeptides’ Accelerated Approval Filing for Melflufen in US Unimpeded by COVID-19

News

Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in the U.S. for the treatment of triple-refractory ... Read more

February 28, 2020February 28, 2020

CLR 131 Helps Heavily Treated Multiple Myeloma Patients, Phase 2 Data Show

News

Cellectar Biosciences’ lead candidate CLR 131 safely and effectively prevents disease progression or reduces tumors in people with hard-to-treat multiple myeloma, according to data from a Phase 2 clinical ... Read more

January 31, 2020January 31, 2020

Researchers Provide Highlights on Study into Benefits of Reolysin, Kyprolis Combo in Multiple Myeloma

News

Researchers are continuing to study how the combination of Oncolytics Biotech‘s virus-based anti-cancer therapy Reolysin (pelareorep) and Kyprolis (carfilzomib) provides benefits in multiple myeloma patients, according to a recent conference call. ... Read more

Pin It on Pinterest